Contact • Charitable Giving

Johns Hopkins Sjogrens Center


donate to the Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center

  • Sjögren’s Syndrome Information
    • Diagnosis of Sjögren’s Syndrome
    • Sjögren’s Syndrome Symptoms
    • Treatment of Sjogren’s Syndrome
    • Sjögren’s Syndrome Disease Education Video Series
  • About The Center
    • Meet Our Team
    • Physician Referral Information
    • Schedule An Appointment
    • Directions
  • Research
    • The SICCA International Registry
  • Support the Center
  • Contact Us

Sjögren’s Syndrome Disease Education Series

July 24, 2018 By Wes Linda

Sjögren’s Syndrome is easy to overlook or misdiagnose, making many patients feel frustrated. In this five-part video series, Dr. Alan Baer validates those who suffer from this disease, and informs those who don’t, about the common misconceptions and challenges that Sjögren’s patients face every day.

1)  Disease Overview

2) Signs & Symptoms

3) Diagnosis

4) Treatment

5) Lifestyle Options

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a study drug in Subjects with Sjögren’s Syndrome

October 6, 2016 By Wes Linda

You could be eligible to participate in the SSAD clinical trial, to find out if the experimental drug is safe and effective in treating people with Sjögren’s Syndrome.

The trial is being sponsored by Elli Lilly and Company

Visit www.clinicaltrials.gov to learn about this study

Identifier: NCT02614716

What the study consists of:

  • A screening that will be completed in 2 visits to review your medical history and determine if you are eligible to participate
  • A treatment phase of 16 weeks duration
    • Visits occur at every 2 or 4 weeks
  • A post-treatment follow-up phase of 12 weeks
  • The study is expected to last 28 weeks

Phase: 1
Study Type: Interventional
Study Design: Randomized

Principal Investigator:

Thomas Grader-Beck, MD, PhD

Study Visit Location:

The Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center
Johns Hopkins Bayview Medical Center
Baltimore, MD

For more information contact:

Ana Manzano
Research Program Coordinator
Telephone: 410-550-6492

A Study to Assess the Efficacy of RO5459072 in Participants with Sjögren’s Syndrome

October 6, 2016 By Wes Linda

You may be eligible to participate in a clinical research study involving an experimental drug. This clinical trial is currently recruiting participants to see how safe and effective an investigational drug, RO5459072 is in treating disease activity and symptoms of primary Sjögren’s Syndrome.

Visit www.clinicaltrials.gov to learn about this study

Registration Number: NCT02701985
Sponsor: F. Hoffman-La Roche, Ltd
Adults Eligible for Study: Ages 18 – 75 years

What the study consists of:

  • A screening that will be completed in 2 visits to review your medical history and determine if you are eligible to participate
  • A treatment phase of 12 weeks duration
    • Study visits occur every 4 weeks
  • A post-treatment follow-up phase

Phase: 2
Study Type: Interventional
Study Design: Randomized
Study #: IRB00098901

Principal Investigator:

Alan Baer, MD
The Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center
The Johns Hopkins Bayview Medical Center
Baltimore, MD 21224

For more information contact:

Ana Manzano
Research Program Coordinator
Telephone: 410-550-6492
Email: ana.manzano@jhmi.edu

Search Our Site

  • Meet Our Team
  • Physician Referral Information
  • Schedule An Appointment
  • Directions

Recent News

  • Sjögren’s Syndrome Disease Education Series
  • A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a study drug in Subjects with Sjögren’s Syndrome
  • A Study to Assess the Efficacy of RO5459072 in Participants with Sjögren’s Syndrome
U.S. News and World Report Rankings Badge

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Rheumatology · Patient Privacy · Copyright © 2019 Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center